Q1 EPS Forecast for CRISPR Therapeutics Increased by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Leerink Partnrs upped their Q1 2025 earnings estimates for CRISPR Therapeutics in a note issued to investors on Monday, February 24th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($1.25) per share for the quarter, up from their prior estimate of ($1.33). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.28) EPS, Q3 2025 earnings at ($1.29) EPS, Q4 2025 earnings at ($1.34) EPS and FY2026 earnings at ($5.09) EPS.

CRSP has been the subject of a number of other reports. Evercore ISI upgraded CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and lifted their price objective for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Chardan Capital lowered their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a report on Wednesday, February 12th. Finally, Morgan Stanley upped their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus price target of $74.40.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $44.51 on Wednesday. The stock has a market capitalization of $3.82 billion, a P/E ratio of -10.19 and a beta of 1.67. CRISPR Therapeutics has a 52 week low of $36.52 and a 52 week high of $90.62. The stock has a fifty day moving average of $42.29 and a 200-day moving average of $46.00.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

Insider Activity

In other news, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Ameriflex Group Inc. bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $36,000. Highline Wealth Partners LLC acquired a new position in CRISPR Therapeutics during the fourth quarter worth $39,000. Western Pacific Wealth Management LP boosted its holdings in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics in the 3rd quarter valued at $40,000. Finally, Darwin Wealth Management LLC bought a new stake in CRISPR Therapeutics during the 3rd quarter worth about $43,000. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.